A5080529259- Inflammatory Bowel Disease
- Microscopic Colitis
- SARS-CoV-2 and COVID-19 Research
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Biosimilars and Bioanalytical Methods
- Celiac Disease Research and Management
- Systemic Lupus Erythematosus Research
- Vaccine Coverage and Hesitancy
- Diagnosis and treatment of tuberculosis
- Dysphagia Assessment and Management
- Tuberculosis Research and Epidemiology
- Liver Disease Diagnosis and Treatment
- Gastrointestinal disorders and treatments
- Pancreatitis Pathology and Treatment
- Inflammatory Myopathies and Dermatomyositis
- Helicobacter pylori-related gastroenterology studies
- Pharmaceutical studies and practices
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- COVID-19 Clinical Research Studies
- Whipple's Disease and Interleukins
- COVID-19 and healthcare impacts
- Autoimmune and Inflammatory Disorders Research
University Hospital of Heraklion
2017-2025
Chania General Hospital ”St. George”
2021-2025
University of Crete
2003-2023
University Gastroenterology
2018
Abstract Background There is limited information in the literature regarding long term effectiveness and safety of anti-TNFa agents patients with Inflammatory Bowel Disease (IBD). We aimed to study IBD receiving this treatment beyond 10 years . Methods Consecutive under >10 were prospectively studied. Demographic clinical characteristics as well details outcomes recorded based on an updated registry. Outcomes included need for optimization [dose escalation or immunosuppressant (IMM)...
Abstract Background Up to 15% of inflammatory bowel disease (IBD) patients are diagnosed after the age 60 years. The aim study was compare characteristics and management IBD before (adult onset-AO) or years (elderly onset-EO). Methods Data a prospective longitudinal registry followed in tertiary center over twelve-year period (2012-2024) were analyzed. Consecutive with complete data at entry included. They divided into two groups according their diagnosis <60 (AO) ≥ (EΟ) compared for...
Abstract Background Anemia is the most common extraintestinal manifestation in inflammatory bowel disease (IBD) (1). The laboratory evaluation and determination of anemia IBD remains challenging (2). aim this study was to evaluate burden, risk factors types patients Crete. Methods This a cross sectional where consecutive were included. Demographic, clinical data [Hemoglobin (Hgb), Ferritin (Fer)] recorded (based on an updated registry) while serums collected Soluble transferrin receptor...
Abstract Background Up to 30% of patients with inflammatory bowel disease (IBD) develop malignancies during their course whichconstitutes the second cause death, after cardiovascular diseases (1,2), similar general population. The present study aims investigate prevalence, risk factors and clinical outcomes in IBD. Methods This is a retrospective study, based on prospectively recorded data from IBD registries two tertiary centres 2012-2022. Patients who developed malignancy were compared...
Abstract Introduction Anti-SARS-CoV-2 vaccine clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease [IBD]. We aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients’ concerns, and side effect profile vaccines, using real-world data. Methods An anonymous web-based self-completed survey was distributed in 36 European countries between June July 2021. The results patient characteristics, status, were...
Infliximab trough levels (IFX-TLs) and antibodies to infliximab (ATIs) have been suggested as useful markers for the optimization of treatment in inflammatory bowel disease (IBD). We aimed estimate patterns over time IFX-TLs ATIs IBD patients on maintenance with IFX.Two different measurements were performed (ELISA; Eagle BioSciences) at a 10-month interval using serum samples consecutive IFX. Certain biomarkers [hemoglobin, erythrocyte sedimentation rate, C-reactive protein (CRP), platelets,...
Since inflammatory bowel disease (IBD) patients were excluded from vaccine authorization studies, limited knowledge exists regarding perceptions and unfavorable effects of COVID-19 vaccination in this group. We aimed to investigate the real-world use adverse events (AEs) vaccines Greek IBD patients. Fully vaccinated followed centers invited participate. All filled out an anonymous online survey concerning program, which included information demographics, clinical characteristics, treatment,...
Both muscle-related complaints and elevated serum creatine kinase (CK) levels have been reported in patients with inflammatory bowel disease (IBD) treated infliximab (IFX), mainly as case reports. The aim of this study was to investigate the effect IFX therapy on CK a cohort Greek IBD patients. Demographic, clinical (including muscle complaints), laboratory data consecutive undergoing treatment matched control group without any use biological were retrospectively analyzed. In both groups,...
Abstract Background Four EMA-approved vaccines against SARS-CoV-2 are currently available. Data regarding antibody responses to initial vaccination regimens in patients with inflammatory bowel diseases (IBD) limited. Methods We conducted a prospective, controlled, multicenter study tertiary Greek IBD centers. Participating had completed the (1 or 2 doses, depending on type of COVID-19 vaccine) at least weeks before enrolment. Anti-S1 IgG levels were measured. Demographic and adverse events...
Background and aims This real-world study assessed the impact of golimumab on health-related quality life (HRQoL) other patient-reported outcomes (PROs) in patients with ulcerative colitis over 12 months Greece. Methods GO-LIFE was a noninterventional, prospective, multicenter, 12-month study. Patients who had moderately-to-severely active were naïve to antitumor necrosis factor (anti-TNFα) therapy failed previous conventional therapy. received as per label. The primary endpoint achieving...
The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between development adverse events (AEs) and IFX-TLs has not been sufficiently studied thus far. To investigate possible AEs Greek IBD receiving maintenance treatment IFX.A retrospective analysis registry data Gastroenterology Department University Hospital Heraklion, from at least one available IFX-TL during years 2016 2017 was...
The present study reports about the effect of doxycycline and/or metronidazole on colonization by Candida organisms human gastrointestinal (GI), oropha-ryngeal tract and vagina. Treatment with or for 10 days increased, but not significantly, GI, oropharyngeal vaginal species. combination metronidazole, used same period, caused a significant increase 2.5 log10 CFU/g stools (mean) Candida. Likewise, 2 out 9 patients treated had substantially increased their vagina This effect, however, could...
Whipple's disease is a rare chronic infectious caused by Tropheryma whipplei. The infection mainly affects the small intestine of middle-aged patients, approximately three times more often in males than females causing malabsorption and excessive weight loss but other organs may be affected as well.We describe case 42-year-old woman with history diarrhea evolving for at least last 6 years. diagnosis was confirmed histopathological examination duodenal biopsy samples Periodic acid-Schiff...
Data on the effectiveness of anti-tumor necrosis factor medications in patients with Crohn's disease (CD) poor prognostic factors (PPFs) are scarce. This study aimed to generate real-world evidence effect early (≤24 months after diagnosis) vs delayed (>24 months) initiation adalimumab (ADL) 26-week remission rate (Harvey-Bradshaw Index ≤4) these patients.This multicentre, retrospective, chart review performed 10 Greek hospitals enrolled adult moderate severe CD ≥8) ≥3 PPFs who were initiated...
Abstract Objectives Elderly hospitalized patients with inflammatory bowel disease (IBD) flare and concurrent Clostridioides difficile infection (CDI) are considered at high risk of IBD-related complications. We aimed to evaluate the short-,intermediate-, long-term post-discharge complications among these patients. Methods A retrospective multicenter cohort study assessing outcomes elderly individuals (≥60 years) for an IBD who were tested CDI (either positive or negative) discharged. The...
The home-performed fecal calprotectin (FC) test has been proposed for the remote management of inflammatory bowel disease (IBD) patients. We present our real-world experience on use FC home testing in IBD patients under maintenance treatment with adalimumab.Consecutive adalimumab were studied retrospectively basis prospectively recorded data. (IBDoc, Βühlmann Laboratories AG, Schönenbuch, Switzerland) was analyzed alongside sufficient information baseline characteristics, follow-up data and...
Background We sought to investigate the prevalence of mucocutaneous manifestations (MCM) and potential associations with clinical characteristics in Greek patients IBD. Methods This was a retrospective observational single-center study. Patients IBD diagnosis attending tertiary referral hospital Heraklion, Crete, from January 2010 2020 were included. Data extracted relevant medical information registry. Standard statistical tests, descriptive statistics chi-square, Pearson correlation...
Abstract Background The novel corona virus (SARS-CoV-2) outbreak was declared as a pandemic in March 2020; this prompted the need for rapid vaccine development. Currently four EMA approved vaccines exist but their efficacy and safety data on patients with Inflammatory Bowel diseases are limited. Methods Greek IBD patients, from 10 tertiary referral centres, who had completed initial vaccination protocol available anti-COVID-19 at least two weeks before enrolment, were prospectively studied....
Smoking has been associated with lower levels of anti-TNF agents, higher antibodies and a reduced response to in patients inflammatory bowel disease (IBD). The aim this study was investigate the possible association between smoking adverse events (AEs) biologics IBD.Consecutive IBD under from prospective, longitudinal registry tertiary center were included. A specially designed questionnaire including wide range AEs also used.A total 147 [median age (IQR) 46 (32.5-56) years, Crohn's (CD) 109...